Millennium Management
MOLN

Millennium Management’s Molecular Partners MOLN Stock Holding History

Millennium Management’s Portfolio MOLN Stock Details MOLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-23,942
Closed -$485K – 7293
2022
Q1 		$485K Sell
23,942
-8,383
-26% -$204K ﹤0.01% 5149
2021
Q4 		$624K Sell
32,325
-33,705
-51% -$567K ﹤0.01% 4851
2021
Q3 		$1.3M Sell
66,030
-2,115
-3% -$41.6K ﹤0.01% 4395
2021
Q2 		$1.39M Buy
+68,145
New +$1.35M ﹤0.01% 4345

Other funds holding MOLN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
HNWAG
High Net Worth Advisory Group Naples, Florida $471M AUM 22.07% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Millennium Management's MOLN Position: Q2 2022 in Review

Millennium Management sold out of Molecular Partners (MOLN) in Q2 2022, closing a stake of 23,942 shares — an estimated $485K sold.

Millennium Management first reported a position in MOLN in Q2 2021 and held it in 4 quarters. The position peaked at $1.39M in Q2 2021. 8 funds tracked by Wall St. Rank hold MOLN as of Q2 2022.

  • Millennium Management reported no remaining Molecular Partners position as of Q2 2022 after selling out during the quarter.
  • Millennium Management sold 23,942 Molecular Partners shares in Q2 2022, an estimated $485K.
  • Millennium Management first reported a position in Molecular Partners in Q2 2021 and held it in 4 quarters.
  • Millennium Management's Molecular Partners position peaked at $1.39M in Q2 2021.
  • 8 funds tracked by Wall St. Rank held Molecular Partners as of Q2 2022.

Based on Millennium Management's 13F filing for Q2 2022, filed 15 Aug 2022.